Reduced absorption of saturated fatty acids and resistance to diet-induced obesity and diabetes by ezetimibe-treated and Npc1l1-/- mice

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 295, Issue 4, 2008, Pages

  Labonté, Eric D ^a   Camarota, Lisa M ^a   Rojas, Juan C ^a   Jandacek, Ronald J ^a   Gilham, Dean E ^a   Davies, Joanna P ^b   Ioannou, Yiannis A ^b   Tso, Patrick ^a   Hui, David Y ^a   Howles, Philip N ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetogenic diet; Glucose metabolism; Insulin sensitivity; Sucrose polybehenate; Western diet

Indexed keywords

EZETIMIBE; FATTY ACID TRANSPORTER 4; LONG CHAIN FATTY ACID; NIEMANN PICK TYPE C 1 LIKE PROTEIN 1; PALMITIC ACID; PROTEIN DERIVATIVE; SATURATED FATTY ACID; STEARIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETOGENESIS; FOOD INTAKE; GENE MUTATION; GLUCOSE INTAKE; GLUCOSE METABOLISM; HYPERGLYCEMIA; INSULIN RESISTANCE; LIPID ABSORPTION; LIPID DIET; MOUSE; NONHUMAN; NPC1L1 GENE; OBESITY; PRIORITY JOURNAL; WEIGHT GAIN;

ANIMALS; AZETIDINES; DIABETES MELLITUS; DIETARY CARBOHYDRATES; DIETARY FATS; FATTY ACID TRANSPORT PROTEINS; FATTY ACIDS; FEMALE; HYPERGLYCEMIA; INTESTINAL ABSORPTION; MALE; MEMBRANE TRANSPORT PROTEINS; MICE; OBESITY;

EID: 57349106472     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.90275.2008     Document Type: Article

References (51)

1. Altmann SW, Davis HR Jr, Yao X, Laverty M, Compton DS, Zhu LJ, Crona JH, Caplen MA, Hoos LM, Tetzloff G, Priestley T, Burnett DA, Strader CD, Graziano MP. The identification of intestinal scavenger receptor class B, type I (SR-BI) by expression cloning and its role in cholesterol absorption. Biochim Biophys Acta 1580: 77-93, 2002.
2. Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N, Graziano MP. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 303: 1201-1204, 2004.
3. Bays HE, Moore PB, Drehobl MA, Rosenblatt S, Toth PD, Dujovne CA, Knopp RH, Lipka LJ, Lebeaut AP, Yang B, Mellars LE, Cuffie-Jackson C, Veltri EP. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 23: 1209-1230, 2001.
4. Besnard P, Niot I, Poirier H, Clement L, Bernard A. New insights into the fatty acid-binding protein (FABP) family in the small intestine. Mol Cell Biochem 239: 139-147, 2002.
5. Blot V, McGraw TE. GLUT4 is internalized by a cholesterol- dependent nystatin-sensitive mechanism inhibited by insulin. EMBO J 25: 5648-5658, 2006.
6. Bray GA, Ryan DH. Drug treatment of the overweight patient. Gastroenterology 132: 2239-2252, 2007.
7. Carter CP, Howles PN, Hui DY. Genetic variation in cholesterol absorption efficiency among inbred strains of mice. J Nutr 127: 1344-1348, 1997.
8. Davies JP, Scott C, Oishi K, Liapis A, Ioannou YA. Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J Biol Chem 280: 12710-12720, 2005.
9. Davis HR Jr, Compton DS, Hoos L, Tetzloff G. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler Thromb Vasc Biol 21: 2032-2038, 2001.
10. -/- mice. Arterioscler Thromb Vasc Biol 27: 841-849, 2007.
11. Davis HR Jr, Zhu LJ, Hoos LM, Tetzloff G, Maguire M, Liu J, Yao X, Iyer SP, Lam MH, Lund EG, Detmers PA, Graziano MP, Altmann SW. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem 279: 33586-33592, 2004.
12. Drover VA, Nguyen DV, Bastie CC, Darlington YF, Abumrad NA, Pessin JE, London E, Sahoo D, Phillips MC. CD36 mediates both cellular uptake of very long chain fatty acids and their intestinal absorption in mice. J Biol Chem 283: 13108-13115, 2008.
13. During A, Dawson HD, Harrison EH. Carotenoid transport is decreased and expression of the lipid transporters SR-BI, NPC1L1, and ABCA1 is downregulated in Caco-2 cells treated with ezetimibe. J Nutr 135: 2305-2312, 2005.
14. Ebine N, Demonty I, Jia X, Jones PJ. Plant stanol ascorbate esters reduce body weight gain through decreased energy absorption in hamsters. Int J Obes (Lond) 30: 751-757, 2006.
15. Ezzet F, Krishna G, Wexler DB, Statkevich P, Kosoglou T, Batra VK. A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe. Clin Ther 23: 871-885, 2001.
16. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, Crona JH, Davis HR Jr, Dean DC, Detmers PA, Graziano MP, Hughes M, Macintyre DE, Ogawa A, O'Neill K A, Iyer SP, Shevell DE, Smith MM, Tang YS, Makarewicz AM, Ujjainwalla F, Altmann SW, Chapman KT, Thornberry NA. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci USA 102: 8132-8137, 2005.
17. Gimeno RE, Hirsch DJ, Punreddy S, Sun Y, Ortegon AM, Wu H, Daniels T, Stricker-Krongrad A, Lodish HF, Stahl A. Targeted deletion of fatty acid transport protein-4 results in early embryonic lethality. J Biol Chem 278: 49512-49516, 2003.
18. Goudriaan JR, Dahlmans VEH, Febbraio M, Teusink B, Romijn JA, Havekes LM, Voshol PJ. Intestinal lipid absorption is not affected in CD36 deficient mice. Mol Cell Biochem 239: 199-202, 2002.
19. Grundy SM, Ahrens EH Jr, Salen G. Dietary beta-sitosterol as an internal standard to correct for cholesterol losses in sterol balance studies. J Lipid Res 9: 374-387, 1968.
20. Hall AM, Wiczer BM, Herrmann T, Stremmel W, Bernlohr DA. Enzymatic properties of purified murine fatty acid transport protein 4 and analysis of acyl-CoA synthetase activities in tissues from FATP4 null mice. J Biol Chem 280: 11948-11954, 2005.
21. Hamilton JA, Brunaldi K. A model for fatty acid transport into the brain. J Mol Neurosci 33: 12-17, 2007.
22. Hirsch D, Stahl A, Lodish HF. A family of fatty acid transporters conserved from mycobacterium to man. Proc Natl Acad Sci USA 95: 8625-8629, 1998.
23. Hofmann SM, Perez-Tilve D, Greer TM, Coburn BA, Grant E, Basford JE, Tschöp MH, Hui DY. Defective lipid delivery modulates glucose tolerance and metabolic response to diet in apolipoprotein E-deficient mice. Diabetes 57: 5-12, 2008.
24. Iyer SP, Yao X, Crona JH, Hoos LM, Tetzloff G, Davis HR Jr, Graziano MP, Altmann SW. Characterization of the putative native and recombinant rat sterol transporter Niemann-Pick C1 Like 1 (NPC1L1) protein. Biochim Biophys Acta 1722: 282-292, 2005.
25. Jandacek RJ, Heubi JE, Tso P. A novel, noninvasive method for the measurement of intestinal fat absorption. Gastroenterology 127: 139-144, 2004.
26. Jia Z, Moulson CL, Pei Z, Miner JH, Watkins PA. Fatty acid transport protein 4 is the principal very long chain fatty acyl-CoA synthetase in skin fibroblasts. J Biol Chem 282: 20573-20583, 2007.
27. Kamp F, Hamilton JA. How fatty acids of different chain length enter and leave cells by free diffusion. Prostaglandins Leukot Essent Fatty Acids 75: 149-159, 2006.
28. Knopfel M, Davies JP, Duong PT, Kvaerno L, Carreira EM, Phillips MC, Ioannou YA, Hauser H. Multiple plasma membrane receptors but not NPC1L1 mediate high-affinity, ezetimibe-sensitive cholesterol uptake into the intestinal brush border membrane. Biochim Biophys Acta 1771: 1140-1147, 2007.
29. Kosoglou T, Meyer I, Veltri EP, Statkevich P, Yang B, Zhu Y, Mellars L, Maxwell SE, Patrick JE, Cutler DL, Batra VK, Affrime MB. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol 54: 309-319, 2002.
30. Labonte ED, Howles PN, Granholm NA, Rojas JC, Davies JP, Ioannou YA, Hui DY. Class B type I scavenger receptor is responsible for the high affinity cholesterol binding activity of intestinal brush border membrane vesicles. Biochim Biophys Acta 1771: 1132-1139, 2007.
31. Levy P, Fried M, Santini F, Finer N. The comparative effects of bariatric surgery on weight and type 2 diabetes. Obes Surg 17: 1248-1256, 2007.
32. Liu P, Leffler BJ, Weeks LK, Chen G, Bouchard CM, Strawbridge AB, Elmendorf JS. Sphingomyelinase activates GLUT4 translocation via a cholesterol-dependent mechanism. Am J Physiol Cell Physiol 286: C317-C329, 2004.
33. McArthur MJ, Atshaves BP, Frolov A, Foxworth WD, Kier AB, Schroeder F. Cellular uptake and intracellular trafficking of long chain fatty acids. J Lipid Res 40: 1371-1383, 1999.
34. Milger K, Herrmann T, Becker C, Gotthardt D, Zickwolf J, Ehehalt R, Watkins PA, Stremmel W, Fullekrug J. Cellular uptake of fatty acids driven by the ER-localized acyl-CoA synthetase FATP4. J Cell Sci 119: 4678-4688, 2006.
35. Nassir F, Wilson B, Han X, Gross RW, Abumrad NA. CD36 is important for fatty acid and cholesterol uptake by the proximal but not distal intestine. J Biol Chem 282: 19493-19501, 2007.
36. Ntanios FY, Jones PJ. Dietary sitostanol reciprocally influences cholesterol absorption and biosynthesis in hamsters and rabbits. Atherosclerosis 143: 341-351, 1999.
37. Patrick JE, Kosoglou T, Stauber KL, Alton KB, Maxwell SE, Zhu Y, Statkevich P, Iannucci R, Chowdhury S, Affrime M, Cayen MN. Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metab Dispos 30: 430-437, 2002.
38. Pohl J, Ring A, Hermann T, Stremmel W. Role of FATP in parenchymal cell fatty acid uptake. Biochim Biophys Acta 1686: 1-6, 2004.
39. Repa J, Turley SD, Quan G, Dietschy JM. Delineation of molecular changes in intrahepatic cholesterol metabolism resulting from diminished cholesterol absorption. J Lipid Res 46: 779-789, 2005.
40. Rubio MA, Gargallo M, Isabel Millán A, Moreno B. Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant. Public Health Nutr 10: 1200-1205, 2007.
41. Stahl A, Hirsch DJ, Gimeno RE, Punreddy S, Ge P, Watson N, Patel S, Kotler M, Raimondi A, Tartaglia LA, Lodish HF. Identification of the major intestinal fatty acid transport protein. Mol Cell 4: 299-308, 1999.
42. Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble DL, Shah S, Perevozskaya I, von Bergmann K. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 106: 1943-1948, 2002.
43. Toth PP, Davidson MH. Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia. Expert Opin Pharmacother 6: 131-139, 2005.
44. Van Bennekum A, Werder M, Thuahnai ST, Han CH, Duong P, Williams DL, Wettstein P, Schulthess G, Phillips MC, Hauser H. Class B scavenger receptor-mediated intestinal absorption of dietary beta-carotene and cholesterol. Biochemistry 44: 4517-4525, 2005.
45. Van Heek M, Austin TM, Farley C, Cook JA, Tetzloff GG, Davis HR. Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters. Diabetes 50: 1330-1335, 2001.
46. Van Heek M, Compton DS, Davis HR. The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. Eur J Pharmacol 415: 79-84, 2001.
47. Van Heek M, Farley C, Compton DS, Hoos L, Davis HR. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol 134: 409-417, 2001.
48. Wasan KM, Holtorf L, Subramanian R, Cassidy SM, Pritchard PH, Stewart DJ, Novak E, Moghadasian MH. Assessing plasma pharmacokinetics of cholesterol following oral coadministration with a novel vegetable stanol mixture to fasting rats. J Pharm Sci 90: 23-28, 2001.
49. Wasan KM, Najafi S, Peteherych KD, Pritchard PH. Effects of a novel hydrophilic phytostanol analog on plasma lipid concentrations in gerbils. J Pharm Sci 90: 1795-1799, 2001.
50. Waseem T, Mogensen KM, Lautz DB, Robinson MK. Pathophysiology of obesity: why surgery remains the most effective treatment. Obes Surg 17: 1389-1398, 2007.
51. Yu L, Bharadwaj S, Brown JM, Ma Y, Du W, Davis MA, Michaely P, Liu P, Willingham MC, Rudel LL. Cholesterol-regulated translocation of NPC1L1 to the cell surface facilitates free cholesterol uptake. J Biol Chem 281: 6616-6624, 2006.